The overarching goal of this NRSA application is to provide a high quality, mentored training experience to develop future thought leaders in cardiovascular clinical research. We will conduct national searches to attract the most promising post-doctoral cardiology fellows into a rigorous clinical research training program that will provide: 1) rigorous didactic training in the methods of clinical research, 2) closely mentored rea world research experience, and 3) structured training and experience in """"""""survival skills"""""""" required for a successful academic career. Trainees will spend at least 2 years in this program and devote 100% effort to the program while they are supported. We are requesting 6 trainee slots at the post-doctoral level. We have selected mentors for the program from among the thought leaders in cardiovascular clinical research at Duke. Ongoing assessment and training of participating faculty mentors on the essentials of good mentoring will be a major feature of our program. Interdisciplinary co-mentoring will be required, with each trainee co-mentored by a methodologist. In addition, trainees will be able to select additional co-mentors from among the excellent faculty participating in this program as well as from among other Duke faculty, depending on each trainee's needs and research interests. For each trainee, several methods will be used to monitor progress, including the creation of a formal Individual Development Plan that will be reviewed regularly by a Scientific Oversight Committee and annually by an External Advisory Board. Outcomes expected from each fellow accepted into this T32 program will include scientific presentations at research conferences/symposia and at national meetings, peer-reviewed publications, an independent research project, and at least one grant application to support the trainee's post-fellowship research. The Program Directors and faculty will assist each graduate in obtaining a faculty position in academics and will further guide and support them as they transition to independent investigators. The proposed NRSA program will organize the abundant resources available at Duke for clinical research into a focused and efficient program for training the cardiovascular clinical research thought leaders of the future.
The purpose of this grant is to train the next generation of thought leaders in cardiovascular clinical research. These clinical researches will bring scientific advancements in the care of patients with cardiovascular disease from bench to bedside through the translation of promising early-phase therapies/treatments into large-scale human testing and will lead research efforts in the comparative effectiveness of new and existing therapies, optimizing systems of care to promote high quality treatment patterns, and epidemiological study. Trainees supported by this grant are expected to make major scientific contributions to medicine in their academic research careers and have a significant impact on public health.
|Vaduganathan, Muthiah; Samman Tahhan, Ayman; Greene, Stephen J et al. (2018) Globalization of heart failure clinical trials: a systematic review of 305 trials conducted over 16 years. Eur J Heart Fail 20:1068-1071|
|Fudim, Marat; O'Connor, Christopher M; Dunning, Allison et al. (2018) Aetiology, timing and clinical predictors of early vs. late readmission following index hospitalization for acute heart failure: insights from ASCEND-HF. Eur J Heart Fail 20:304-314|
|Alenezi, Fawaz; Mandawat, Aditya; Il'Giovine, Zachary J et al. (2018) Clinical Utility and Prognostic Value of Right Atrial Function in Pulmonary Hypertension. Circ Cardiovasc Imaging 11:e006984|
|Friedman, Daniel J; Al-Khatib, Sana M (2018) Response by Friedman and Al-Khatib to Letter Regarding Article, ""Ventricular Fibrillation Conversion Testing After Implantation of a Subcutaneous Implantable Cardioverter Defibrillator: Report From the National Cardiovascular Data Registry"". Circulation 138:2972-2973|
|Greene, Stephen J; Mentz, Robert J; Fiuzat, Mona et al. (2018) Reassessing the Role of Surrogate End Points in Drug Development for Heart Failure. Circulation 138:1039-1053|
|Ambrosy, Andrew P; Mentz, Robert J; Fiuzat, Mona et al. (2018) The role of angiotensin receptor-neprilysin inhibitors in cardiovascular disease-existing evidence, knowledge gaps, and future directions. Eur J Heart Fail 20:963-972|
|Greene, Stephen J; Felker, G Michael; Butler, Javed (2018) Outpatient versus inpatient worsening heart failure: distinguishing biology and risk from location of care. Eur J Heart Fail :|
|Greene, Stephen J; Mentz, Robert J (2018) Potential advantages of torsemide in patients with heart failure: more than just a 'water pill'? Eur J Heart Fail 20:471-473|
|Mandawat, Aditya; Newby, L Kristin (2018) High-Sensitivity Troponin in Noncardiac Surgery: Pandora's Box or Opportunity for Precision Perioperative Care? Circulation 137:1233-1235|
|Greene, Stephen J; Fonarow, Gregg C; Solomon, Scott D et al. (2018) Relationship between timing of trial randomization, protocol completion, and clinical outcomes among patients hospitalized for heart failure: from the ASTRONAUT trial. Eur J Heart Fail :|
Showing the most recent 10 out of 186 publications